SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Ovid Therapeutics Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

690469101

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP Number(s):

690469101

Names of Reporting Persons

Eventide Asset Management, LLC

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 12,773,577.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 12,773,577.00
8	Shared Dispositive Power 0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

12,773,577.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

7.3 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP Number(s):

690469101

Names of Reporting Persons

Finny Kuruvilla, M.D., Ph. D.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 12,773,577.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 12,773,577.00

Aggregate Amount Beneficially Owned by Each Reporting Person

12,773,577.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

7.3 %

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP Number(s):

690469101

Names of Reporting Persons

Robin C. John

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 12,773,577.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 12,773,577.00

Aggregate Amount Beneficially Owned by Each Reporting Person

12,773,577.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

7.3 %

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Ovid Therapeutics Inc.

(b)

Address of issuer's principal executive offices:

441 Ninth Avenue, 14th floor, New York, NY 10001

Item 2.

(a)

Name of person filing:

(i) Eventide Asset Management, LLC ("Eventide") (ii) Finny Kuruvilla, M.D., Ph.D. ("Kuruvilla") (iii) Robin C. John ("John")

(b)

Address or principal business office or, if none, residence:

Eventide, Kuruvilla and John: One International Place, Suite 4210 Boston, Massachusetts 02110

(c)

Citizenship:

Eventide: Delaware Kuruvilla: United States John: United States

(d)

Title of class of securities:

Common Stock, par value $0.001 per share

(e)

CUSIP Number(s):

690469101

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

(i) Eventide: 12,773,577 (ii) Kuruvilla: 12,773,577 (iii) John: 12,773,577

(b)

Percent of class:

(i) Eventide: 7.3% (ii) Kuruvilla: 7.3% (iii) John: 7.3%

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

(1) Eventide: 12,773,577 (2) Kuruvilla: 0 (3) John: 0

(ii) Shared power to vote or to direct the vote:

(1) Eventide: 0 (2) Kuruvilla: 12,773,577 (3) John: 12,773,577

(iii) Sole power to dispose or to direct the disposition of:

(1) Eventide: 12,773,577 (2) Kuruvilla: 0 (3) John: 0

(iv) Shared power to dispose or to direct the disposition of:

(1) Eventide: 0 (2) Kuruvilla: 12,773,577 (3) John: 12,773,577

Item 5.

Ownership of 5 Percent or Less of a Class.

Not Applicable

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

As of March 31, 2026, Eventide Asset Management, LLC, a Delaware limited liability company located at One International Place, Suite 4210, Boston, Massachusetts 02110, is the beneficial owner of 12,773,577 shares of the Issuer's Common Stock by virtue of being the investment adviser to Eventide Healthcare & Life Sciences Fund which is a registered investment company. As of March 31, 2026, the Eventide Healthcare & Life Sciences Fund held 12,773,577 shares of the Issuer's Common Stock, representing 7.3% of the Issuer's outstanding Common Stock.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Eventide Asset Management, LLC

Signature:	/s/ Peter J. Luiso
Name/Title:	Peter J. Luiso, General Counsel
Date:	05/15/2026

Finny Kuruvilla, M.D., Ph. D.

Signature:	/s/ Finny Kuruvilla, M.D., Ph. D.
Name/Title:	Finny Kuruvilla, M.D., Ph. D.
Date:	05/15/2026

Robin C. John

Signature:	/s/ Robin C. John
Name/Title:	Robin C. John
Date:	05/15/2026

Exhibit Information

EXHIBIT 1 - Filed Herewith

SEC Form SCHEDULE 13G filed by Ovid Therapeutics Inc.